Literature DB >> 12873590

Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?

Mohamad A Eloubeidi1, Andrew C Mason, Renee A Desmond, Hashem B El-Serag.   

Abstract

OBJECTIVE: The incidence and mortality related to esophageal adenocarcinoma (EAC) has been rising in the United States. Meanwhile, the number of diagnostic and therapeutic procedures has increased in number and improved technologically. However, the impact of these advances on the survival of EAC in clinical practice remains unknown.
METHODS: Patients with histologically proven EAC between 1973 and 1997 were identified in registries of the Surveillance, Epidemiology, and End Results database, and analyzed in 5-yr time periods. The observed and relative survival rates were calculated. The joint influence of the time of diagnosis, stage and grade of cancer, demographic features, surgical therapy, and radiotherapy were assessed in Cox proportional hazard survival analyses.
RESULTS: Between 1973 and 1997, we identified 4835 patients with EAC. The 1-yr and 5-yr observed survival rates increased from 34% and 5% during 1973-1977 to 44% and 13% during 1993-1997 (p < 0.05). In the Cox survival analysis, the more recent year of diagnosis, early stage of tumor, younger age at presentation, receiving radiotherapy or surgery were independent predictors of reduced risk of mortality. The proportion of patients with in situ EAC and those with local spread increased progressively from 0.3% and 17.7% in 1973-1977 to 2.3% and 25.3%, respectively, in 1993-1997 (p < 0.05). The proportion of patients receiving radiation therapy either before or after surgery has increased from 7% in 1973-1977 to 16% in 1993-1997 (p < 0.05).
CONCLUSIONS: The short- and long-term survival of patients with EAC has improved slightly in the United States over the past 25 yr. Some of the improvement may be related to an increase in the number of younger patients, and in cases with in situ and localized cancers. However, the overall survival of patients with EAC remains dismal.

Entities:  

Mesh:

Year:  2003        PMID: 12873590     DOI: 10.1111/j.1572-0241.2003.07454.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  72 in total

Review 1.  Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms.

Authors:  Shelby D Melton; Robert M Genta; Rhonda F Souza
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-05       Impact factor: 46.802

Review 2.  Angle-resolved low-coherence interferometry: an optical biopsy technique for clinical detection of dysplasia in Barrett's esophagus.

Authors:  Yizheng Zhu; Neil G Terry; Adam Wax
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-02       Impact factor: 3.869

3.  Association of insulin and insulin-like growth factors with Barrett's oesophagus.

Authors:  Katarina B Greer; Cheryl L Thompson; Lacie Brenner; Beth Bednarchik; Dawn Dawson; Joseph Willis; William M Grady; Gary W Falk; Gregory S Cooper; Li Li; Amitabh Chak
Journal:  Gut       Date:  2011-09-19       Impact factor: 23.059

4.  A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  Juan W Valle; Anne Armstrong; Chris Newman; Valery Alakhov; Grzegorz Pietrzynski; Julie Brewer; Sue Campbell; Pippa Corrie; Eric K Rowinsky; Malcolm Ranson
Journal:  Invest New Drugs       Date:  2010-02-24       Impact factor: 3.850

Review 5.  Screening and surveillance of Barrett's esophagus.

Authors:  Jeff Michalak; Ajay Bansal; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2009-06

6.  Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus.

Authors:  Kazuhiro Yasuda; Sung Eun Choi; Norman S Nishioka; David W Rattner; William P Puricelli; Angela C Tramontano; Seigo Kitano; Chin Hur
Journal:  Dig Dis Sci       Date:  2014-01-07       Impact factor: 3.199

Review 7.  Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.

Authors:  Florian Rieder; Piero Biancani; Karen Harnett; Lisa Yerian; Gary W Falk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-18       Impact factor: 4.052

8.  Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus.

Authors:  Junichi Akiyama; Samuel N Marcus; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2012-08-10       Impact factor: 3.199

9.  Feasibility of a simplified narrow-band imaging classification system for Barrett's esophagus for novice endoscopists.

Authors:  Hiroto Furuhashi; Kenichi Goda; Yuichi Shimizu; Masayuki Kato; Masakazu Takahashi; Akira Dobashi; Koji Hirata; Ayane Oba; Taku Shigesawa; Masaki Inoue; Hiroaki Matsui; Chika Kinoshita; Yoshitaka Ando; Masahiro Ikegami; Tadakazu Shimoda; Mototsugu Kato
Journal:  J Gastroenterol       Date:  2019-01-02       Impact factor: 7.527

10.  Gallstones increase the prevalence of Barrett's esophagus.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Keiko Asakura; Yoshimasa Saito; Kenro Hirata; Toru Takebayashi; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2009-11-12       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.